What is Monte Rosa Therapeutics, Inc.'s depreciation?

Monte Rosa Therapeutics, Inc. (GLUE) reported depreciation of $2.03M in Q1 2026.

How has Monte Rosa Therapeutics, Inc.'s depreciation changed year-over-year?

Monte Rosa Therapeutics, Inc.'s depreciation decreased by 0.9% year-over-year, from $2.05M to $2.03M.

What is the long-term trend for Monte Rosa Therapeutics, Inc.'s depreciation?

Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s depreciation has grown at a 41.5% compound annual growth rate (CAGR), from $2.08M to $8.36M.

Monte Rosa Therapeutics, Inc. GLUE Depreciation

Depreciation at other companies

Cogent Biosciences, Inc.COGT

——

Adaptive BiotechnologiesADPT

——

Immunovant, Inc.IMVT

——

Apogee Therapeutics, Inc.APGE

——

Oruka Therapeutics, Inc.ORKA

——

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s depreciation?: Monte Rosa Therapeutics, Inc. (GLUE) reported depreciation of $2.03M in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s depreciation changed year-over-year?: Monte Rosa Therapeutics, Inc.'s depreciation decreased by 0.9% year-over-year, from $2.05M to $2.03M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s depreciation?: Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s depreciation has grown at a 41.5% compound annual growth rate (CAGR), from $2.08M to $8.36M.